Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;31(8):1515-1517.
doi: 10.1007/s00192-020-04319-z. Epub 2020 May 12.

Vaginal laser for overactive bladder syndrome

Ioannis Charalampous  1 , Visha K Tailor  2 , Alex Digesu  3
Affiliations

Vaginal laser for overactive bladder syndrome

Ioannis Charalampous et al. Int Urogynecol J. 2020 Aug.

Abstract

Overactive bladder syndrome (OAB) is defined as urinary urgency, usually with urinary frequency and nocturia, with or without urge urinary incontinence. The prevalence of OAB in adult women ranges between 11% and 42%, is particularly common in elderly people, and can overlap with the genitourinary syndrome of menopause (GSM). There is a wide approach to the treatment of symptoms, often in a stepwise fashion, including lifestyle changes, bladder retraining and pelvic floor muscle rehabilitation, drug therapy, intra-vesical botulinum toxin injections or neuromodulation. Recently, vaginal laser therapy has been proposed as an emerging minimal invasive effective treatment option for women with OAB. We explore this further.

Keywords: Overactive bladder syndrome; Vaginal laser.

PubMed Disclaimer

Conflict of interest statement

None.

References

    1. Hsu FC, Weeks CE, Selph SS, Blazina I, Holmes RS, McDonagh MS. Updating the evidence on drugs to treat overactive bladder: a systematic review. Int Urogynecol J. 2019;30(10):1603–1617. doi: 10.1007/s00192-019-04022-8. - DOI - PMC - PubMed
    1. Bhide AA, Khullar V, Swift S, Digesu GA. The use of laser in urogynaecology. Int Urogynecol J. 2019;30(5):683–692. doi: 10.1007/s00192-018-3844-7. - DOI - PMC - PubMed
    1. Shobeiri SA, Kerkhof MH, Minassian VA, Bazi T. IUGA Research and Development Committee. IUGA committee opinion: laser-based vaginal devices for treatment of stress urinary incontinence, genitourinary syndrome of menopause, and vaginal laxity. Int Urogynecol J. 2019;30(3):371–376. doi: 10.1007/s00192-018-3830-0. - DOI - PubMed
    1. Tranoulis A, Georgiou D, Michala L. Laser treatment for the management of genitourinary syndrome of menopause after breast cancer. Hope or hype? Int Urogynecol J. 2019;30(11):1879–1886. doi: 10.1007/s00192-019-04051-3. - DOI - PubMed
    1. Garcia B, Pardo J. Academic cosmetic gynecology and energy-based therapies: ambiguities, explorations, and FDA advisories. Int Urogynecol J. 2019;30(1):1–2. doi: 10.1007/s00192-018-3812-2. - DOI - PubMed